Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 4 Date: 31 Aug 2024
Reviewer's report:
Thank you for your revisions. The manuscript is significantly improved, but a few areas still
need correction.
1. Thanks for the clarification regarding hormonal anti-inflammatory therapy. Typically, we
refer to these medications simply as corticosteroids instead of “glucocorticoid hormonal anti-
inflammatory therapy”.
2. Results section of the abstract:
a) What do you mean by “Crohn’s disease who were naïve”? Do you mean naïve to therapy or
naïve to biologics.
b) “Ulcerative colitis who were naïve to biological agents” – In the main text, it was stated that
these patients were naïve to all treatment not just to biologics. Please clarify.
c) Please double check all the numbers provided in the abstract to ensure accuracy. For example,
it is stated in the abstract that “clinical response rate of patients with Crohn’s disease who were
naïve was 0.80 (95% CI, 0.75-0.85)”. However, in the main text, it is stated that “the total pooled
rate of clinical response rates on patients with CD was 0.81%, 95% CI (0.76 to 0.85).”
d) Please provide the follow up interval for the results reported in the abstract
3. Conclusion sentence of the abstract needs to be more informative.
Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 4 Date: 31 Aug 2024
Reviewer's report:
Thank you for your revisions. The manuscript is significantly improved, but a few areas still
need correction.
1. Thanks for the clarification regarding hormonal anti-inflammatory therapy. Typically, we
refer to these medications simply as corticosteroids instead of “glucocorticoid hormonal anti-
inflammatory therapy”.
2. Results section of the abstract:
a) What do you mean by “Crohn’s disease who were naïve”? Do you mean naïve to therapy or
naïve to biologics.
b) “Ulcerative colitis who were naïve to biological agents” – In the main text, it was stated that
these patients were naïve to all treatment not just to biologics. Please clarify.
c) Please double check all the numbers provided in the abstract to ensure accuracy. For example,
it is stated in the abstract that “clinical response rate of patients with Crohn’s disease who were
naïve was 0.80 (95% CI, 0.75-0.85)”. However, in the main text, it is stated that “the total pooled
rate of clinical response rates on patients with CD was 0.81%, 95% CI (0.76 to 0.85).”
d) Please provide the follow up interval for the results reported in the abstract
3. Conclusion sentence of the abstract needs to be more informative.
Please review this paper.
user
Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 4 Date: 31 Aug 2024
Reviewer's report:
Thank you for your revisions. The manuscript is significantly improved, but a few areas still
need correction.
1. Thanks for the clarification regarding hormonal anti-inflammatory therapy. Typically, we
refer to these medications simply as corticosteroids instead of “glucocorticoid hormonal anti-
inflammatory therapy”.
2. Results section of the abstract:
a) What do you mean by “Crohn’s disease who were naïve”? Do you mean naïve to therapy or
naïve to biologics.
b) “Ulcerative colitis who were naïve to biological agents” – In the main text, it was stated that
these patients were naïve to all treatment not just to biologics. Please clarify.
c) Please double check all the numbers provided in the abstract to ensure accuracy. For example,
it is stated in the abstract that “clinical response rate of patients with Crohn’s disease who were
naïve was 0.80 (95% CI, 0.75-0.85)”. However, in the main text, it is stated that “the total pooled
rate of clinical response rates on patients with CD was 0.81%, 95% CI (0.76 to 0.85).”
d) Please provide the follow up interval for the results reported in the abstract
3. Conclusion sentence of the abstract needs to be more informative.
assistant